This can be the case for metabolic diseases, such as metabolic syndrome, obesity, and type 2 diabetes mellitus (T2DM), as well as some auto-inflammatory disorders [33-35], which may benefit from IL-1β blockers, or even NLRP3 inflammasome inhibitory therapies. This evidence concerns the gene IL1B and type 2 diabetes mellitus.